Clinical Relapses of Atypical HUS on Eculizumab: Clinical Gap for Monitoring and Individualised Therapy

Atypical hemolytic uremic syndrome (aHUS) is caused by dysregulation of the complement system. A humanised anti-C5 monoclonal antibody (eculizumab) is available for the treatment of aHUS. We present the first description of atypical HUS in a child with a coexistent diagnosis of a POL-III leukodystro...

Descripción completa

Detalles Bibliográficos
Autores principales: Teoh, Chia Wei, Gorman, Kathleen Mary, Lynch, Bryan, Goodship, Timothy H. J., Dolan, Niamh Marie, Waldron, Mary, Riordan, Michael, Awan, Atif
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2018
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5818949/
https://www.ncbi.nlm.nih.gov/pubmed/29552364
http://dx.doi.org/10.1155/2018/2781789

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5818949/
https://www.ncbi.nlm.nih.gov/pubmed/29552364
http://dx.doi.org/10.1155/2018/2781789

Ejemplares similares